an active metabolite of the topoisomerase I inhibitor irinotecan, with a humanised monoclonal antibody (hRS7 IgG1κ) targeting the Trop-2 antigen. Trop-2 is overexpressed in many epithelial tumours, including breast cancer subtypes, with particularly high levels in TNBC [87,88]. Clinical trials, ...
an active metabolite of the topoisomerase I inhibitor irinotecan, with a humanised monoclonal antibody (hRS7 IgG1κ) targeting the Trop-2 antigen. Trop-2 is overexpressed in many epithelial tumours, including breast cancer subtypes, with particularly high levels in TNBC [87,88]. Clinical trials, ...
Studies with PARP inhibitors have demonstrated promising results in the treatment of BRCA-mutated breast and ovarian cancer, and PARP inhibitors have been studied as monotherapy and in combination with cytotoxic therapy or radiotherapy. PARP inhibitor efficacy on poly (ADP-ribose) polymer (PAR) ...
[2] Dorling L,Carvalho S,Allen J,et al. Breast cancer risk genes-association analysis in more than 113,000 women [J]. N Engl J Med,2021,384(5):428-439. [3] Li H,Liu ZY,Wu N,et al. PARP inhibitor resistance:the under...
Parp Inhibitor Treatment of Advanced Breast Cancer Beyond the BRCA-Mutated Type: A Meta-Analysis Feifei Yan, Qi Jiang, Mengye He & Peng Shen Pages 2381-2393 | Received 16 Nov 2020, Accepted 26 Feb 2021, Published online: 31 Mar 2021 Cite this article https://doi.org/10.2217/fon-2020-117...
[2] AstraZeneca eyes a safer PARP inhibitor, with nearly 50% response in advanced breast cancer patients: #AACR24. Retrieved April 8, 2024, from https://endpts.com/astrazeneca-eyes-a-safer-parp-inhibitor-with-nearly-50-response-in-advanc...
PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway 2021, Biochimica et Biophysica Acta - Reviews on Cancer Citation Excerpt : Genetic testing of BRCA1/2 in advanced-stage OC revealed that numerous abnormalities in tumor samples,...
ShRNA lentiviral vectors were used to knockdown 53BP1 expression in breast cancer cell lines. Phospho-ATM and 53BP1 protein expressions were determined in human breast cancer tissues by immunohistochemistry (IHC). We show that inhibiting ATM increased cytotoxicity of PARP inhibitor in triple-negative...
The addition of the cyclin dependent kinase inhibitor (CDKi) dinaciclib to Poly-(ADP-ribose) polymerase inhibitor (PARPi) therapy is a strategy to overcome resistance to PARPi in tumors that exhibit homologous recombination (HR) deficiencies as well as t
Results from the SWOG S1416 clinical trial show that adding veliparib to chemotherapy can significantly extend progression-free survival (PFS) times in patients with triple-negative breast cancer (TNBC) that has a "BRCA-like" phenotype.